Clinical Medical College, Chengdu Medical College, Chengdu, Sichuan, China.
Department of Oncology, The First Affiliated Hospital of Chengdu Medical College, Chengdu, Sichuan, China.
BMC Cancer. 2024 Nov 4;24(1):1351. doi: 10.1186/s12885-024-13104-w.
This study aimed to systematically analyze the efficacy and toxicity of lurbinectedin as a second-line or subsequent treatment for extensive-stage small cell lung cancer (ES-SCLC).
Candidate studies were identified in PubMed, Embase, Cochrane Library, ClinicalTrials.gov, CNKI, and Wanfang databases up to 1 May 2024. Objective remission rate (ORR), disease control rate (DCR), duration of response (DOR), progression-free survival (PFS), overall survival (OS), and adverse events (AEs) were extracted, respectively. The efficacy and toxicity of lurbinectedin in ES-SCLC were analyzed by meta-analysis.
Six eligible prospective studies were included in this meta-analysis, including 536 patients with ES-SCLC who received second-line or subsequent treatment. In pooled analysis, the ORR of lurbinectedin was 35% (95% confidence interval [CI] 29-41), DCR was 67% (95%CI 58-76), DOR was 5.33 months (95%CI 4.51-6.16), PFS was 3.38 months (95%CI 2.59-4.17), and OS was 7.49 months (95%CI 5.11-9.87). The incidence of AEs and severe adverse events (SAEs) was 92% (95%CI 78-100) and 37% (95%CI 19-57), respectively. The most common AEs were leukopenia, neutropenia, anemia, and thrombocytopenia, with incidences of 81% (68-91), 74% (57-88), 73% (35-98) and 57% (46-68), respectively.
As a promising alternative for second-line treatment for ES-SCLC, lurbinectedin has a certain level of efficacy and a favorable safety profile. The integration of lurbinectedin with other therapeutic modalities presents an emerging area warranting further investigation.
本研究旨在系统分析吕滨尼定作为广泛期小细胞肺癌（ES-SCLC）二线或后续治疗的疗效和毒性。
截至 2024 年 5 月 1 日，在 PubMed、Embase、Cochrane 图书馆、ClinicalTrials.gov、CNKI 和万方数据库中确定候选研究。分别提取客观缓解率（ORR）、疾病控制率（DCR）、缓解持续时间（DOR）、无进展生存期（PFS）、总生存期（OS）和不良事件（AE）。采用荟萃分析分析吕滨尼定治疗 ES-SCLC 的疗效和毒性。
本荟萃分析纳入了 6 项合格的前瞻性研究，共纳入 536 例接受二线或后续治疗的 ES-SCLC 患者。汇总分析显示，吕滨尼定的 ORR 为 35%（95%CI 29-41），DCR 为 67%（95%CI 58-76），DOR 为 5.33 个月（95%CI 4.51-6.16），PFS 为 3.38 个月（95%CI 2.59-4.17），OS 为 7.49 个月（95%CI 5.11-9.87）。AE 和严重不良事件（SAE）发生率分别为 92%（95%CI 78-100）和 37%（95%CI 19-57）。最常见的 AE 是白细胞减少、中性粒细胞减少、贫血和血小板减少，发生率分别为 81%（68-91）、74%（57-88）、73%（35-98）和 57%（46-68）。
作为 ES-SCLC 二线治疗的一种有前途的选择，吕滨尼定具有一定的疗效和良好的安全性。吕滨尼定与其他治疗方式的联合应用是一个值得进一步研究的新兴领域。
